PwC’s Pharmaceutical & Life Sciences network is pleased to present you with our eighth issue of the Asia-Pacific Pharmaceutical & Life Sciences industry newsletter.
This issue includes Special Reports on the recent Indian and Singapore Budgets and the implications for multinationals and the local Pharma and Healthcare sectors.
In our Compliance section we report on China’s recent crackdowns on fake drugs to improve the safety and sustainability of China’s pharmaceuticals industry.
From an M&A perspective, we have a brief summary on the causes of the fall in M&A activity in Korea over the last 5 years.
Our section on Pricing developments once more includes further articles on moves by various Governments to control and reduce overall drug pricing within major markets in the region.
Finally, in our Tax section, major changes to Transfer Pricing rules have been announced in Australia and Indonesia which will have wider implications for the region.
In addition, there’s further news from Japan, New Zealand, Taiwan and Thailand with a special focus on some new biotech incentives in Malaysia.